Praxis Precision Medicines (PRAX) Long-Term Investments (2024 - 2026)

Praxis Precision Medicines' Long-Term Investments history runs 3 years deep, the most recent figure standing at $660.9 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 358.88% year-over-year to $660.9 million in Q1 2026; TTM through Mar 2026 was $660.9 million, a 358.88% increase from a year earlier, with the FY2025 full-year figure at $326.8 million, up 324.57% from the prior year.
• Long-Term Investments climbed to $660.9 million in Q1 2026 per PRAX's latest filing, from $326.8 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $660.9 million in Q1 2026 and bottomed at $35.9 million in Q1 2024.
• The 3-year median for Long-Term Investments is $122.0 million (2025), against an average of $183.1 million.
• Across the five-year window, Long-Term Investments jumped 77.38% in 2025 and soared 358.88% in 2026, its largest moves.
• Year by year, Long-Term Investments stood at $77.0 million in 2024, then jumped by 324.57% to $326.8 million in 2025, then surged by 102.27% to $660.9 million in 2026.
• Per Business Quant, the three latest PRAX Long-Term Investments figures stand at $660.9 million (Q1 2026), $326.8 million (Q4 2025), and $122.0 million (Q3 2025).